ATE311174T1 - Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung - Google Patents

Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung

Info

Publication number
ATE311174T1
ATE311174T1 AT99930689T AT99930689T ATE311174T1 AT E311174 T1 ATE311174 T1 AT E311174T1 AT 99930689 T AT99930689 T AT 99930689T AT 99930689 T AT99930689 T AT 99930689T AT E311174 T1 ATE311174 T1 AT E311174T1
Authority
AT
Austria
Prior art keywords
nasal
compositions
pulmonary administration
compositions containing
delivery
Prior art date
Application number
AT99930689T
Other languages
English (en)
Inventor
Zahir Saidi
Boris Klyashchitsky
Original Assignee
Lds Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lds Technologies Inc filed Critical Lds Technologies Inc
Application granted granted Critical
Publication of ATE311174T1 publication Critical patent/ATE311174T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
AT99930689T 1998-06-26 1999-06-24 Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung ATE311174T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/105,838 US6241969B1 (en) 1998-06-26 1998-06-26 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
PCT/US1999/014351 WO2000000181A1 (en) 1998-06-26 1999-06-24 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery

Publications (1)

Publication Number Publication Date
ATE311174T1 true ATE311174T1 (de) 2005-12-15

Family

ID=22308060

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99930689T ATE311174T1 (de) 1998-06-26 1999-06-24 Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung

Country Status (8)

Country Link
US (1) US6241969B1 (de)
EP (1) EP1089715B8 (de)
JP (1) JP4875239B2 (de)
AT (1) ATE311174T1 (de)
AU (1) AU4717199A (de)
CA (1) CA2335900C (de)
DE (1) DE69928665T2 (de)
WO (1) WO2000000181A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
EP1143930B8 (de) * 1999-09-11 2008-03-19 Glaxo Group Limited Fluticasonpropionat arzneizubereitung
EP1244426A4 (de) * 1999-12-23 2004-10-06 Robert E Coifman Verfahren und formulierungen zur effizienten verabreichung wasserunlöslicher arzneistoffe mittels eines verneblers
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
HU230804B1 (hu) 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
AU2002310054B2 (en) * 2001-05-21 2007-02-01 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
ES2316571T3 (es) * 2001-05-24 2009-04-16 Alexza Pharmaceuticals, Inc. Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria.
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
DE60302454T2 (de) * 2002-04-19 2006-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
AU2003239433A1 (en) 2002-05-13 2003-11-11 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
WO2003100333A2 (en) * 2002-05-21 2003-12-04 University Of Massachusetts Low pressure impact separator for separation, classification and collection of ultra­fine particles
EP1509209A1 (de) * 2002-05-23 2005-03-02 UMD, Inc. Zusammensetzungen und verfahren für die transmukosale arzneimittelabgabe und kryoprotektion
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004004640A2 (en) * 2002-07-05 2004-01-15 Tetragrammaton Inc. Methods, compositions and kits for treating damage to excitable tissue
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040045546A1 (en) 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
EP1562975A2 (de) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroide welche gruppen zur nachahmung von superoxidase dismutase sowie stickoxid donorgruppen beinhalten und ihre verwendung in der darstellung von medikamenten
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PT1567164E (pt) * 2002-11-26 2009-03-31 Alexza Pharmaceuticals Inc Utilização de loxapina para o fabrico de um medicamento para o tratamento da dor
CN1726037B (zh) * 2002-11-26 2010-05-05 艾利斯达医药品公司 抗精神病药用于制备通过吸入传送治疗头痛的药物中的应用
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
DE60323138D1 (de) * 2002-12-12 2008-10-02 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
KR20060002922A (ko) * 2003-03-31 2006-01-09 알자 코포레이션 비수성 단일 상 비히클 및 이러한 비히클을 이용한 제형
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
ES2452691T5 (es) * 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1729724A4 (de) 2003-12-31 2008-07-23 Cydex Inc Inhalationsformulierung mit sulfoalkylether-gamma-cyclodextrin und corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
US7892483B2 (en) * 2004-03-12 2011-02-22 Cipla Limited Sterilization process
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2486942B1 (de) * 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Zusammensetzungen mit azelastin und anwendungsverfahren
EP1888026A4 (de) * 2005-05-27 2012-07-04 Taro Pharmaceuticals North America Inc Stabile flüssigformulierung mit desoximetason und isopropylmyristat mit reduzierter oxidierter verunreinigung während langzeitiger lagerung
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009526619A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 質量減量を伴うコルチコステロイドの滅菌
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
FR2916974B1 (fr) * 2007-06-11 2010-11-26 Univ Angers Procede de preparation de nanoparticules lipidiques
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009064458A2 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
DK2389372T3 (en) 2009-01-23 2015-12-14 Rigel Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITION OF JAK pathway
JP2013518097A (ja) 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
PL2366408T3 (pl) * 2010-03-01 2013-01-31 Salvat Lab Sa Klarowne roztwory wodne acetonidu fluocinolonu do leczenia zapalenia uszu
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
WO2014197398A1 (en) * 2013-06-03 2014-12-11 Tolmar, Inc. Corticosteroid compositions
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
WO2015109201A1 (en) 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Budesonide cyclodextrin formulation
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
EP4013420B1 (de) 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Verfahren zur blockierung oder linderung des zytokinfreisetzungssyndroms
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US20230303555A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US5208226A (en) 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
EP0580778B1 (de) 1991-04-19 1999-08-11 LDS Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
ATE134509T1 (de) 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US5314207A (en) 1992-06-10 1994-05-24 Roadmaster Corporation Bicycle with simulated motorcycle parts
CA2142103C (en) 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
JPH09157157A (ja) * 1995-12-01 1997-06-17 Pola Chem Ind Inc 医薬組成物
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs

Also Published As

Publication number Publication date
AU4717199A (en) 2000-01-17
JP2002519318A (ja) 2002-07-02
DE69928665D1 (de) 2006-01-05
WO2000000181A1 (en) 2000-01-06
EP1089715A4 (de) 2004-03-31
EP1089715B8 (de) 2006-02-01
US6241969B1 (en) 2001-06-05
CA2335900C (en) 2009-04-14
EP1089715B1 (de) 2005-11-30
JP4875239B2 (ja) 2012-02-15
DE69928665T2 (de) 2006-08-10
EP1089715A1 (de) 2001-04-11
CA2335900A1 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
ATE311174T1 (de) Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung
MX2007012802A (es) Composicion farmaceutica en aerosol.
RU2607892C2 (ru) Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции
JP3636430B2 (ja) フォルモテロールを含む貯蔵可能な活性物質濃縮物
WO2002085297A3 (en) Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
ATE526956T1 (de) Viruzide zusammensetzungen
HK1085390A1 (en) Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases
UA71585C2 (uk) Стійкий при зберіганні концентрат біологічно активної речовини формотеролу
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
HRP20021025B1 (hr) Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom
JP2019517597A5 (de)
WO2006026083A3 (en) Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
JP2002519318A5 (de)
DE60131088D1 (de) Gelierende wässrige pharmazeutische zusammensetzungen
CN108289898B (zh) 在雌性猪属动物中刺激生殖的信息素组合物及其使用方法
JP5667060B2 (ja) 乾癬を治療するための安定化組成物
WO2004024122A1 (en) Composition and method for moisturizing nasal tissue
US20090325917A1 (en) Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
Wu et al. Pulmonary and nasal anti-inflammatory and anti-allergy inhalation aerosol delivery systems
AR008309A1 (es) Formulaciones de aerosol en suspensión de furoato de mometasona , usos de de las mismas e inhalador de dosis de medida
MXPA03007748A (es) Composiciones que destruyen virus.
WO2005011608A3 (en) PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR
JP5079257B2 (ja) Ｂｕｒｋｈｏｌｄｅｒｉａｃｅｐａｃｉａに対する保存剤
CN105520944A (zh) 一种稳定的吸入用茶碱乙酸氨溴索溶液
JP2004075571A (ja) 点鼻剤およびその製造方法

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties